Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects

Area of Science:

• Pharmaceutical Science
• Medicinal Chemistry
• Drug Development

Background:

• Peptide-based therapeutics (PbTs) exhibit high selectivity, efficacy, and low toxicity, driving pharmaceutical interest.
• Pharmacopoeias establish critical standards and testing methods for PbTs.
• Current pharmacopoeial approaches for PbTs lack global harmonization.

Purpose of the Study:

• To provide an overview of pharmacopoeial methodologies and specifications for PbTs.
• To identify key differences in PbT monographs across various pharmacopoeias.
• To discuss the potential for PbTs to become a significant therapeutic class.

Main Methods:

• Review of current pharmacopoeial monographs for peptide-based therapeutics.
• Comparative analysis of methodologies and specifications.
• Identification of discrepancies in focus on active pharmaceutical ingredients.

Main Results:

• Significant variations exist in pharmacopoeial test procedures for PbTs.
• Differences are noted in the active pharmaceutical ingredients prioritized by various pharmacopoeias.
• Lack of harmonization may impede global pharmaceutical industry engagement with PbTs.

Conclusions:

• Harmonizing pharmacopoeial monographs for PbTs is essential for their advancement.
• Standardized approaches will foster greater global industry adoption of PbTs.
• PbTs hold substantial promise for development into a mature therapeutic niche.